» Articles » PMID: 9409366

Improving Interobserver Variation in Reporting Gadolinium-enhanced MRI Lesions in Multiple Sclerosis

Overview
Journal Neurology
Specialty Neurology
Date 1997 Dec 31
PMID 9409366
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Gadolinium-enhanced MRI is a sensitive and objective means to monitor disease activity in multiple sclerosis (MS). We evaluated the interobserver agreement and the value of observer training in reporting enhancing lesions from serial MRI. Scans of 16 MS patients were evaluated by five inexperienced and five experienced observers before and after consensus formation and training. The number of lesions at baseline, and the number of new and persistent lesions at follow-up were scored. For each condition, weighted kappa values (kappa) and the mean average difference to the median (MADM) scores were calculated. Without training, the experienced readers showed good agreement on number of lesions at baseline and new lesions at follow-up, and moderate agreement for persistent lesions. The inexperienced readers showed poor agreement for baseline and persistent lesions, and moderate agreement for new lesions. After training, both groups reported lower absolute numbers of lesions, especially the inexperienced readers. The experienced readers showed good agreement for all lesion types, the inexperienced readers showed agreement for baseline and new lesions, and agreement was moderate for persistent lesions. In both groups MADM scores were < 0.72 for baseline and new lesions, but > 1.2 for persistent lesions. Interobserver agreement is improved by training, especially in inexperienced readers. Interobserver agreement in reporting gadolinium-enhanced lesions is high, which validates the use of serial, enhanced MRI as an outcome parameter in treatment trials in MS.

Citing Articles

Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging.

Eisele P, Fischer K, Szabo K, Platten M, Gass A Front Neurol. 2019; 10:1082.

PMID: 31681152 PMC: 6813212. DOI: 10.3389/fneur.2019.01082.


Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.

Filippi M, Rocca M, Bastianello S, Comi G, Gallo P, Gallucci M Neurol Sci. 2013; 34(12):2085-93.

PMID: 23828372 DOI: 10.1007/s10072-013-1485-7.


Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Erbayat Altay E, Fisher E, Jones S, Hara-Cleaver C, Lee J, Rudick R JAMA Neurol. 2013; 70(3):338-44.

PMID: 23599930 PMC: 3792494. DOI: 10.1001/2013.jamaneurol.211.


Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.

Zivadinov R, Hojnacki D, Hussein S, Bergsland N, Carl E, Durfee J Int J Mol Sci. 2012; 13(5):5659-5673.

PMID: 22754322 PMC: 3382749. DOI: 10.3390/ijms13055659.


MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

Barkhof F, Simon J, Fazekas F, Rovaris M, Kappos L, De Stefano N Nat Rev Neurol. 2011; 8(1):13-21.

PMID: 22143362 DOI: 10.1038/nrneurol.2011.190.